249 related articles for article (PubMed ID: 34232070)
1. Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.
Anand SP; Ding S; Tolbert WD; Prévost J; Richard J; Gil HM; Gendron-Lepage G; Cheung WF; Wang H; Pastora R; Saxena H; Wakarchuk W; Medjahed H; Wines BD; Hogarth M; Shaw GM; Martin MA; Burton DR; Hangartner L; Evans DT; Pazgier M; Cossar D; McLean MD; Finzi A
J Virol; 2021 Aug; 95(18):e0079621. PubMed ID: 34232070
[TBL] [Abstract][Full Text] [Related]
2. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
Tuyishime M; Garrido C; Jha S; Moeser M; Mielke D; LaBranche C; Montefiori D; Haynes BF; Joseph S; Margolis DM; Ferrari G
J Clin Invest; 2020 Oct; 130(10):5157-5170. PubMed ID: 32584790
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
4. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
5. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
[TBL] [Abstract][Full Text] [Related]
7. Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells.
Richard J; Nguyen DN; Tolbert WD; Gasser R; Ding S; Vézina D; Yu Gong S; Prévost J; Gendron-Lepage G; Medjahed H; Gottumukkala S; Finzi A; Pazgier M
mBio; 2021 Oct; 12(5):e0140521. PubMed ID: 34579568
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
[TBL] [Abstract][Full Text] [Related]
10. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.
Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH
J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448
[TBL] [Abstract][Full Text] [Related]
11. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
[TBL] [Abstract][Full Text] [Related]
13. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
[TBL] [Abstract][Full Text] [Related]
14. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques.
Rosenberg YJ; Lewis GK; Montefiori DC; LaBranche CC; Lewis MG; Urban LA; Lees JP; Mao L; Jiang X
PLoS One; 2019; 14(2):e0212649. PubMed ID: 30785963
[TBL] [Abstract][Full Text] [Related]
15. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
[TBL] [Abstract][Full Text] [Related]
17. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
18. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
[TBL] [Abstract][Full Text] [Related]
19. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
Front Immunol; 2018; 9():244. PubMed ID: 29651286
[TBL] [Abstract][Full Text] [Related]
20. Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses.
Richard J; Prévost J; Baxter AE; von Bredow B; Ding S; Medjahed H; Delgado GG; Brassard N; Stürzel CM; Kirchhoff F; Hahn BH; Parsons MS; Kaufmann DE; Evans DT; Finzi A
mBio; 2018 Mar; 9(2):. PubMed ID: 29559570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
